1. Home
  2. PTCT vs TMDX Comparison

PTCT vs TMDX Comparison

Compare PTCT & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTCT
  • TMDX
  • Stock Information
  • Founded
  • PTCT 1998
  • TMDX 1998
  • Country
  • PTCT United States
  • TMDX United States
  • Employees
  • PTCT N/A
  • TMDX N/A
  • Industry
  • PTCT Biotechnology: Pharmaceutical Preparations
  • TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • PTCT Health Care
  • TMDX Health Care
  • Exchange
  • PTCT Nasdaq
  • TMDX Nasdaq
  • Market Cap
  • PTCT 5.3B
  • TMDX 3.9B
  • IPO Year
  • PTCT 2013
  • TMDX 2019
  • Fundamental
  • Price
  • PTCT $76.19
  • TMDX $117.33
  • Analyst Decision
  • PTCT Buy
  • TMDX Buy
  • Analyst Count
  • PTCT 17
  • TMDX 11
  • Target Price
  • PTCT $73.24
  • TMDX $130.73
  • AVG Volume (30 Days)
  • PTCT 1.1M
  • TMDX 1.0M
  • Earning Date
  • PTCT 11-04-2025
  • TMDX 10-29-2025
  • Dividend Yield
  • PTCT N/A
  • TMDX N/A
  • EPS Growth
  • PTCT N/A
  • TMDX 170.70
  • EPS
  • PTCT 8.94
  • TMDX 2.54
  • Revenue
  • PTCT $1,779,150,000.00
  • TMDX $566,354,000.00
  • Revenue This Year
  • PTCT $119.02
  • TMDX $38.84
  • Revenue Next Year
  • PTCT N/A
  • TMDX $20.46
  • P/E Ratio
  • PTCT $8.46
  • TMDX $46.16
  • Revenue Growth
  • PTCT 97.54
  • TMDX 41.20
  • 52 Week Low
  • PTCT $35.95
  • TMDX $55.00
  • 52 Week High
  • PTCT $77.46
  • TMDX $145.50
  • Technical
  • Relative Strength Index (RSI)
  • PTCT 81.34
  • TMDX 45.02
  • Support Level
  • PTCT $69.23
  • TMDX $111.04
  • Resistance Level
  • PTCT $73.98
  • TMDX $125.57
  • Average True Range (ATR)
  • PTCT 2.83
  • TMDX 7.52
  • MACD
  • PTCT 0.35
  • TMDX -1.59
  • Stochastic Oscillator
  • PTCT 91.85
  • TMDX 19.88

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Share on Social Networks: